Moderate

Autoimmune (IgG4-related) pancreatitis

AIP · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Steroid-responsive fibroinflammatory pancreatitis; type 1 is the pancreatic manifestation of IgG4-related disease, type 2 is duct-centric and associated with IBD. A key mimic of pancreatic cancer.

Figures & algorithms

Atlanta classification
Atlanta classification

Red flags

  • Features suggesting malignancy (discrete mass, weight loss, rising CA19-9)
  • Cholangitis with obstructive jaundice
  • Failure to respond to steroids (reconsider cancer)
  • Multi-organ IgG4 disease progression

Assessment

Differential diagnosis

  • Pancreatic adenocarcinoma
  • Chronic (alcohol-related) pancreatitis
  • Cholangiocarcinoma (if biliary strictures)
  • Primary sclerosing cholangitis
  • Lymphoma

Investigations

  • Serum IgG4 (elevated in type 1)
  • Cross-sectional imaging: diffuse 'sausage' pancreas with rim/halo, delayed enhancement
  • MRCP/ERCP: long/multifocal main pancreatic duct strictures without upstream dilatation
  • EUS-guided biopsy (storiform fibrosis, lymphoplasmacytic infiltrate, IgG4+ plasma cells)
  • Assess other organ involvement (biliary, renal, salivary, retroperitoneal fibrosis)

Management

  • Suspect AIP in painless obstructive jaundice or a pancreatic mass with raised IgG4 or other-organ involvement
  • Critically exclude pancreatic/biliary malignancy — AIP is a cancer mimic
  • Combine imaging, serology, histology and other-organ involvement (e.g. ICDC criteria) to diagnose
  • Obtain tissue (EUS biopsy) where malignancy cannot be confidently excluded
  • Induce remission with corticosteroids — most patients respond rapidly
  • Relieve biliary obstruction with stenting if significant jaundice/cholangitis
  • Taper steroids over weeks to months with clinical and biochemical monitoring
  • Use a steroid-sparing immunomodulator or rituximab for relapse/maintenance in type 1
  • Monitor for and treat exocrine and endocrine insufficiency
  • Screen for and manage associated IgG4 disease in other organs
  • Arrange long-term follow-up given relapse tendency

Drugs & doses

Prednisolone 0.6–0.8 mg/kg/day PO (typically 30–40 mg) then taper
Azathioprine 2–2.5 mg/kg/day PO (maintenance/relapse)
Rituximab (refractory/relapsing type 1, specialist)
Pancreatic enzyme replacement if exocrine insufficiency

Disposition

Pancreaticobiliary MDT; hepatology/gastroenterology follow-up for immunosuppression and relapse surveillance.

Complications & pitfalls

  • Misdiagnosis as pancreatic cancer (unnecessary surgery) or vice versa
  • Biliary strictures and cholangitis
  • Exocrine and endocrine (diabetes) insufficiency
  • Relapse requiring immunosuppression
  • Steroid side effects

Exam pearls

  • A dramatic steroid response supports AIP, but exclude cancer first — never steroid-trial a possible malignancy without tissue
  • Raised IgG4 is suggestive but not diagnostic; it can be normal in type 2 and mildly raised in cancer
  • Type 2 AIP is associated with inflammatory bowel disease
  • Relapse is common in type 1; maintenance immunosuppression or rituximab may be needed

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.